You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

To UNSUBSCRIBE from this list, or change your e-mail address, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

Please do not reply to this message.
_______________________________________________

On September 19, 2005, FDA approved several generic formulations of Zidovudine for the U.S. market.

Previously, the products had been only tentatively approved and were not available in the United States because patent or market exclusivity blocked their approval for domestic marketing. With the expiration of those patents, the following products have received full marketing authorization for the United States: 
(1) zidovudine  tablets, 300 mg , manufactured by Ranbaxy Laboratories Limited of Guragon, India;
(2) zidovudine tablets, 300 mg and oral solution, 50 mg/5mL, manufactured by Aurobindo Pharma LTD. Hyderabad, India; and
(3) zidovudine tablets, 300 mg,  manufactured by Roxane Laboratories of Columbus, Ohio, U.S.A. 

These are the first generic versions of the already-approved Retrovir brand manufactured by GlaxoSmithKline to be approved for marketing in the U.S.  FDA previously determined, as part of a tentative approval action, that these products meet all U.S. manufacturing quality and clinical safety and efficacy standards.

Zidovudine is in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing.  This antiretroviral drug is intended to be used with other antiretroviral agents for the treatment of HIV infection.

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html